Navigation Links
Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Date:9/24/2007

ANN ARBOR, Mich. Sept. 24 /PRNewswire/ -- Velcura Therapeutics, Inc., a biotechnology company developing therapies for bone disease, met with the U.S. Food and Drug Administration (FDA) Sept. 20 to clarify details for the early clinical development of VEL-0230, a drug developed to treat bone disease. The focus of the Pre-Investigational New Drug Application (IND) meeting was to obtain feedback from the FDA's Division of Oncology Drug Products about Velcura's completed preclinical studies, as well as Velcura's near-term clinical development plans for VEL-0230. VEL-0230 is a new chemical entity that has dual-acting properties that both stimulates bone formation and inhibits loss. The company, a 2007 Michigan 50 Companies to Watch award winner, plans to initiate clinical trials in 2008 for the use of this drug as a treatment for Multiple Myeloma, a blood cancer associated with profound bone loss.

Michael W. Long, PhD, President and Chief Executive Officer of Velcura, said, "We appreciate the thoughtful, comprehensive and responsive feedback we received in our pre-IND meeting with the FDA. This clear regulatory advice and direction will greatly assist our IND application planned for late 2007. Our laboratory investigations, in vivo animal models, and extensive non- clinical toxicology evaluations demonstrate that VEL-0230 is a safe and effective molecule. Its dual-action bone properties make it an ideal therapy for multiple bone diseases," Dr. Long added.

VEL-0230 is being studied preclinically for the treatment of diseases involving bone mineral disorders such as bone loss related to multiple myeloma, osteoporosis, bone metastases, and rheumatoid arthritis. Given VEL- 0230's promotion of bone formation, inhibition of bone loss and reduction of calcium levels, Velcura has chosen Myeloma as its lead indication, as the bone fragility, bone pain, high calcium levels and eventual kidney involvement present serious medical and quality of life issues to aff
'/>"/>

SOURCE Velcura Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... N.Y. , Dec. 24, 2014 Kinex ... dosed with KX2-361 at Roswell Park Cancer Institute. ... small molecule drug that has shown potent inhibitory activity ... including those that are resistant to Temozolomide (T98G), the ... glioma. In a well-established brain tumor mouse model, KX2-361 ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, ... PTN), a biopharmaceutical company developing targeted, receptor-specific peptide ... unmet medical need and commercial potential, today announced ... of 2,050,000 shares of its common stock and ... its common stock.  Funds under the management of ...
(Date:12/24/2014)... 2014 ResMed (NYSE: RMD ) today ... Chinese medical device manufacturer BMC Medical Co., Ltd. ... masks listed below infringe ResMed,s patents, and entered an order ... the United States : , ... , Willow nasal pillows mask , iVolve full face ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... SALT LAKE CITY, June 04, 2007 /PRNewswire-FirstCall/ -- ... a 340 patient,randomized Phase III clinical trial testing ... presented at the annual,American Society of Clinical Oncology ... results of this clinical study,which was conducted at ...
... III Data Presented at ASCO -, CHICAGO, ... that Soliris(TM) (eculizumab), a new treatment for,paroxysmal ... , is effective in patients diagnosed with ... (AA) or myelodysplastic,syndromes (MDS). Soliris significantly reduced ...
Cached Medicine Technology:Hyperthermia Plus Chemotherapy Nearly Doubles Disease-Free Survival,Compared to Chemotherapy Alone for Sarcoma Cancer Patients 2Hyperthermia Plus Chemotherapy Nearly Doubles Disease-Free Survival,Compared to Chemotherapy Alone for Sarcoma Cancer Patients 3Soliris Effective in PNH Patients With History of Aplastic Anemia,and Myelodysplastic Syndromes 2Soliris Effective in PNH Patients With History of Aplastic Anemia,and Myelodysplastic Syndromes 3Soliris Effective in PNH Patients With History of Aplastic Anemia,and Myelodysplastic Syndromes 4Soliris Effective in PNH Patients With History of Aplastic Anemia,and Myelodysplastic Syndromes 5Soliris Effective in PNH Patients With History of Aplastic Anemia,and Myelodysplastic Syndromes 6Soliris Effective in PNH Patients With History of Aplastic Anemia,and Myelodysplastic Syndromes 7
(Date:12/26/2014)... Yisrayl Hawkins, Pastor at The House of Yahweh in ... the Ferguson, Missouri unrest. Yisrayl starts his letter by showing ... it has only increased. , He continues in his ... there is a very specific reason for mankind and covers ... set of rules, or Laws that if followed would ensure ...
(Date:12/26/2014)... PA (PRWEB) December 26, 2014 Pentec ... Work in the state of Pennsylvania for 2014. The ... first statewide programs of its kind in the country. ... Foundation, the Pennsylvania Department of Community and Economic Development, ... Resource Management and the Central Penn Business Journal. ...
(Date:12/25/2014)... The click strand woven bamboo flooring ... Today, the business announces a click strand woven ... 30, 2015. , Click strand woven bamboo flooring ... a well-known brand in the bamboo industry. It ... reliable bamboo flooring supplier. , “We are happy ...
(Date:12/25/2014)... 26, 2014 Recently, iFitDress.com, the popular online ... has announced its new selection of black one-shoulder cocktail ... sale now; they are available at discounted prices, up to ... promotion will last for three weeks only. You know, we ... who are interested in our new items can visit our ...
(Date:12/25/2014)... December 25, 2014 Helen Harris’ RP ... Woodland Hills, California after an 8 year battle with ... Christmas Eve evening in her home in Woodland Hills ... breast cancer. , As the founder ... years, she pioneered and championed many of today's greatest ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... ... to promote their first documentary film project entitled Now Serving. Now Serving will highlight the lives ... , ... Box Media LLC announces the launch of their blog site, My Apple Box , which ...
... ... that MedFusion®, of Dallas, Texas, has signed a business agreement to license laboratory ... ... 17, 2010 -- Sunquest Information Systems, Inc. ® , a leading provider ...
... ... can talk with an animated character - called an Avatar - who can help you make ... playing the role of an irate partner. , ... New York, NY (PRWEB) March 17, 2010 -- Imago,s new "marriage counseling" Avatar ...
... ... and potential physician leaders, through New York University,s Stern School of Business. , ... (Vocus) March 16, 2010 ... for its current and potential physician leaders. The 10-session program of New York University’s ...
... (Nasdaq: JAZZ ) announced today that Robert Myers , the company,s President, will present at the Barclays Capital 2010 Global Healthcare Conference on Wednesday, March 24, 2010 ... ... ... ...
... , March 16 TeamHealth Holdings, Inc. ("TeamHealth") ... of outsourced healthcare professional staffing and administrative services to hospitals ... today announced that its management will be presenting at the ... 2010 , at the Loews Miami Hotel, Florida . ...
Cached Medicine News:Health News:Announcing the Launch of My Apple Box 2Health News:Sunquest Information Systems Enters into Business Relationship with MedFusion of Dallas 2Health News:Avatar Meets Marriage Counseling; Take Imago Therapy for a Test Drive 2Health News:Avatar Meets Marriage Counseling; Take Imago Therapy for a Test Drive 3Health News:Summit Medical Group Prepares Physicians for Future Leadership 2Health News:Jazz Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference 2Health News:TeamHealth Holdings, Inc., to Present at Barclays Capital Global Healthcare Conference 2Health News:TeamHealth Holdings, Inc., to Present at Barclays Capital Global Healthcare Conference 3
One step Immunochromatographic Assay for the detection of Respiratory Syncytial Virus...
Rapid Immunoassay for the detection of Respiratory Syncytial Virus....
Rapid, visual assay for the presumptive qualitative detection of Respiratory Syncytial Virus (RSV) directly from nasopharyngeal specimens in neonatel and pediatric patients....
... The BD Directigen EZ RSV Test utilizes ... reagent and one device for rapid RSV detection. ... a method whereby dried reagents have already ... reduced to a two-step process, with clear-cut results ...
Medicine Products: